Previsión

El precio objetivo medio de los analistas es de 86,58 € (+36,35 %). La mediana es de 86,58 € (+36,35 %).

Comprar
  10
Mantener
  2
Vender
  0

Debates en la comunidad

Todavía no hay ninguna discusión sobre este activo.

Iniciar debate

  • RadNet beats Q2 forecasts and raises full-year guidance

    RadNet reported adjusted EPS of $0.29 for Q2 2026 on revenue of $622.7m, both well above consensus estimates, and posted an adjusted EBITDA quarterly record of $99.7m. Total revenue rose 25% year over year, driven by stronger demand for advanced imaging and a 56.5% increase in digital-health revenue; ARR nearly doubled to $105.5m. The company raised its full-year targets for imaging revenue, adjusted EBITDA and free cash flow. The stock rose about 6% in after-hours trading, while management highlighted accelerated adoption of AI solutions and continued wage-pressure and integration risks. » Más en de.investing.com


  • RadNet secures $250 million loan and lowers interest costs

    RadNet has amended its existing credit agreement and taken on an additional $250 million loan, which is being combined with the existing facility (totaling $1.2087 billion) and matures on April 18, 2031. Quarterly principal payments will rise from $2.4 million to about $3.1 million. RadNet plans to use the funds for acquisitions, organic growth, healthcare partnerships and general corporate purposes. The interest rate has been cut by 0.25 percentage points (choice of Term SOFR plus 2.00% or an alternate base rate plus 1.00%), and the terms of the revolving credit line were also improved, strengthening the company’s financial flexibility with a cash position of $455 million as of March 31, 2026. » Más en de.investing.com


  • DeepHealth (RadNet subsidiary) launches AI platform Reporting Pro for radiology reporting

    DeepHealth, a wholly owned subsidiary of RadNet, has made Reporting Pro commercially available — an AI-powered platform for creating radiology reports that combines speech recognition, clinical AI findings, measurements, generative AI assessments, and quality assurance in a single workflow. The solution incorporates both FDA-cleared and CE-marked AI tools, can integrate with existing PACS/RIS systems, and supports all imaging modalities. RadNet is rolling out Reporting Pro across its own network, has secured initial external customers, and plans to expand into additional countries by the end of the year. » Más en de.investing.com


  • Moody's cuts rating of RadNet's senior secured bank credit facilities after $200m loan

    Moody’s downgraded RadNet’s senior secured bank credit facilities from Ba3 to B1; the Corporate Family Rating remains at B1 with a stable outlook. The downgrade follows the issuance of an additional $200 million senior loan to finance acquisitions and expansion, which raises pro forma leverage from about 4.5x to around 5.0x. Moody’s cites higher fixed costs and geographic concentration as pressure points, but highlights RadNet’s strong competitive position, revenue diversification and a pro forma liquidity position of more than $600 million, and expects leverage to decline over the next 12–18 months. » Más en de.investing.com


  • RadNet beats revenue forecasts in Q1 2026, stock rises despite EPS miss

    RadNet reported Q1 2026 revenue of $575.63 million versus $557.64 million expected (+3.23% surprise) with EPS of $-0.28 (forecast -$0.15). Revenue rose 22.1% year over year, adjusted EBITDA increased 36.3%, and days sales outstanding (DSO) were 29.5 days. The stock climbed 8.95% in premarket trading to $63.40 as investors reacted positively to revenue growth, digital health initiatives and acquisition contributions. RadNet maintains an upbeat outlook with FY 2026 guidance of $0.63 EPS and expected revenues of $2.45 billion. » Más en de.investing.com

Datos financieros

En el último trimestre, RadNet tuvo unos ingresos de 563,49 M € y un beneficio neto de 3,67 M €

(EUR) septiembre de 2026
YoY
Ingresos 563,49 M 26,47 %
Beneficio bruto 75,81 M 22,74 %
Beneficio neto 3,67 M 20,57 %
EBITDA 84,05 M 27,39 %

Datos fundamentales

Métrica Valor
Capitalización bursátil
5004,59 M €
Número de acciones
78,77 M
Máximo/mínimo de 52 semanas
78,23 € - 46,31 €
Dividendos No
Beta
1,40
Ratio P/E
-242,22
Ratio PEG
3,65
Ratio P/B
4,84
Ratio P/S
2,30

Perfil de la empresa

RadNet, Inc., junto con sus subsidiarias, presta servicios de diagnóstico por imagen ambulatorios en los Estados Unidos. Sus servicios incluyen resonancia magnética, tomografía computarizada, tomografía por emisión de positrones, medicina nuclear, mamografía, ecografía, radiología diagnóstica, fluoroscopia y otros procedimientos relacionados, así como servicios de imagen multimodalidad. La compañía también desarrolla y comercializa sistemas informatizados para la industria del diagnóstico por imagen, incluidos sistemas de archivo y comunicación de imágenes (PACS) y servicios relacionados; y desarrolla e implementa paquetes de inteligencia artificial para mejorar la interpretación de imágenes por parte de los radiólogos en el ámbito de la mamografía, así como soluciones de IA para el cáncer de pulmón y de próstata. A 31 de diciembre de 2021, era propietaria y gestionaba 347 centros en Arizona, California, Delaware, Florida, Maryland, Nueva Jersey y Nueva York. La compañía fue fundada en 1981 y tiene su sede en Los Ángeles, California.

Nombre
RadNet
CEO
Howard G. Berger
Sede Los Angeles, ca
Estados Unidos
Sitio web
Sector
Salud
Industria
Equipos y suministros sanitarios
Salida a bolsa
10/12/2021
Empleados 9060

Símbolos bursátiles

Bolsa Símbolo
NASDAQ
RDNT
Frankfurt
PQIA.F
Düsseldorf
PQIA.DU
SIX
PQIA.SW
🍪

Parqet  usa cookies. Más información